Epstein Secrets

hnology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or s

ug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as hig

hnology changing the world today. Email me, follow me on Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who have established heart disease, for people whose risk of a heart attack or s

ug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Porges, an biotechnology analyst at investment bank Sanford C. Bernstein, found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as hig

body", "text":"Ronny Gal, a securities analyst at Sanford C. Bernstein & Company who follows the pharmaceutical industry, s

80 million to settle a whistle- blower lawsuit claiming it had inappropriately promoted Revlimid and Thalomid to treat a range of cancers beyond what the Food and Drug Administration had approved. Several generic drug companies have sued the company claiming that Celgene denied them access to drug samples needed to make cheaper co